Clinical trial No longer in our active list Observational

Using Magnetocardiography to Assess Chest Pain Risks

Official title: Magnetocardiography in the Identification and Risk Stratification of Patients With Acute Chest Pian

Run by Qilu Hospital of Shandong University · NCT06316011 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study tests if a special heart scan can help doctors understand the risks of chest pain in people who might have a serious heart condition.

Quick facts

Study typeObservational
SexAll
Enrollment3620 (estimated)
SponsorQilu Hospital of Shandong University
Academic / other
Locations1 site (Jinan, Shandong)
Trial IDNCT06316011 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals presenting with symptoms of acute chest pain suspected of acute coronary syndrome.

Probably not a fit

Patients with known structural heart disease, significant arrhythmias, or other critical conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify and stratify the risk of patients presenting with acute chest pain suspected of having acute coronary syndrome (ACS) using Magnetocardiography (MCG). The study will involve a prospective cohort of patients who meet specific inclusion criteria, including those with suspected ACS. Participants will undergo MCG examinations to evaluate their cardiac function and risk levels. The findings may help in better management and treatment decisions for patients with chest pain.

Why it matters

Potential benefit: If successful, this approach could lead to improved risk assessment and management of patients with acute chest pain, potentially reducing adverse outcomes.

How similar studies have gone: While the use of Magnetocardiography is a relatively novel approach, similar studies in cardiac risk assessment have shown promising results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Those with suspected ACS who presented with symptoms of acute chest pain.
* Signed informed consent.

Exclusion Criteria:

* Those with known structural heart disease such as cardiomyopathy and valvular disease;
* Those with atrial fibrillation, supraventricular tachycardia, atrioventricular block and other arrhythmias that have not returned to normal;
* Those who have chest pain with known pulmonary embolism or aortic coarctation;
* Those who are thought to be incapable of completing the MCG examination by an attending physician (or physician with higher qualifications) due to unstable clinical conditions, metal implants, etc;
* Those who are unable to perform magnetocardiography examinations due to claustrophobia, etc., or those who fail to receive magnetocardiography examination;
* Those with malignant tumors;
* Pregnant or lactating women.
* Those with acute or critical illnesses of other systems, such as acute or severe respiratory illnesses, marked abnormalities in liver function or kidney function.

Where it's running

  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.